New combo therapy aims to outsmart resistant lung cancer
Disease control
Recruiting now
This early-phase study tests whether adding carotuximab to the standard drug osimertinib is safe and tolerable for people with advanced EGFR-mutated non-small cell lung cancer. About 60 participants whose cancer has worsened on previous treatments will receive the combination. Th…
Phase: PHASE1 • Sponsor: Karen Reckamp, MD, MS • Aim: Disease control
Last updated May 17, 2026 02:01 UTC